The Future: Think performance enhancers are a problem now?
By David Epstein,
Sports Illustrated
| 03. 11. 2008
Welcome to the era of the genetically engineered superathlete
I am one of the most avid sports fans you'll find," Se-Jin Lee says. It's true. He'll watch anything. Basketball. Football. Fútbol.
Billiards on channel seven-hundred-whatever. As a graduate student in
the '80s Lee used to sit in his car in the driveway with the radio on
to listen to the games of faraway baseball teams. Even now, in his lab
at Johns Hopkins Medical School in Baltimore, he easily rattles off the
NCAA basketball tournament winners in order from 1964 to 2007. And,
like anyone who values fair competition these days, he's disturbed by
the issue of performance-enhancing drugs in sports.
Why, then, is
Lee working to usher in technology that will make even today's most
inventive doping methods look primitive? A professor of molecular
biology and genetics, the 49-year-old Lee studies genes that tell
muscles what to do -- genes that he knows how to change. As clever as
chemists are in altering steroid molecules to avoid detection (recall
BALCO's THG, a.k.a. "the Clear"), those designer drugs can be spotted
once antidoping agencies know what to look for...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...